YBX1 promotes PD-L1-associated CD8 + T cell apoptosis and regulates T cell cytokine secretion by upregulating PD-L1. These findings suggest that endogenous YBX1 plays a role in the development of chemoresistance associated with an induced tumor immunosuppressive microenvironment and immune evasion...
Genetic depletion or pharmacological inhibition of Chek2 with blood-brain-barrier permeable drugs that are in the clinical trials, in combination with PD-1/PD-L1 blockade, led to survival benefit in preclinical glioma models. Analysis of human GBMs demonstrated that Chek2 expression is inversely ...
For example, it is reported that KPNB1 can mediate PD-L1 nuclear translocation and promote non-small cell lung cancer cell proliferation [17]. In breast cancer, suppression of KPNB1 inhibited cancer cell proliferation by abrogating the nuclear transport of Her2 [18]. KPNB1 has also been ...
GFPT2, YBX1, E-cadherin, and N-cadherin were used at a concentration of 1:200. Then the slides were incubated with tyramide-conjugated fluorophore and the nuclei were
Within the nucleus, YBX1 binds to the promoter sequences of PD-L1, an immune checkpoint protein, thereby boosting its transcription [109]. Consequently, this triggers PD-L1-mediated apoptosis of CD8+ T cells and upregulates immunosuppressive molecules like IL-10 and TGF-β. YBX1 also ...